🇺🇸 Fluzone-High Dose Quadrivalent in United States

43 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Headache — 7 reports (16.28%)
  2. Constipation — 5 reports (11.63%)
  3. Product Storage Error — 5 reports (11.63%)
  4. Arthralgia — 4 reports (9.3%)
  5. Condition Aggravated — 4 reports (9.3%)
  6. Nasopharyngitis — 4 reports (9.3%)
  7. Off Label Use — 4 reports (9.3%)
  8. Pain — 4 reports (9.3%)
  9. Abdominal Pain — 3 reports (6.98%)
  10. Back Pain — 3 reports (6.98%)

Source database →

Fluzone-High Dose Quadrivalent in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Fluzone-High Dose Quadrivalent approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Fluzone-High Dose Quadrivalent in United States?

Vanderbilt University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.